The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosisPreclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumoniaResistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosaIn vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis AntibioticsPK/PD models in antibacterial development.Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.Models and approaches for anti-TB drug testing.Targeting persisters for tuberculosis controlNonclinical models for antituberculosis drug development: a landscape analysis.Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.Synergistic activity of synthetic N-terminal peptide of human lactoferrin in combination with various antibiotics against carbapenem-resistant Klebsiella pneumoniae strains.Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant TuberculosisA Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosisOptimal control strategies for disinfection of bacterial populations with persister and susceptible dynamics.Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using In Vitro Experiments and Response-Surface Modeling.Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.Translational Modeling of Antibacterial Agents
P2860
Q26771848-2EA27023-45C6-4FBB-A998-9F732C94A66EQ28540482-655F095D-43C0-49F4-8BEA-32667D5E5355Q33427278-FCCC99E5-351C-45B2-BCEB-42BB54894C69Q35004994-DD3DAE77-E02E-49B7-A1B0-EBFABDFC8699Q35666434-38283A55-3480-4B7D-9AD1-396FA457F2CBQ36056408-CDCC6407-6621-4E75-896D-3AC7C889D091Q37325658-06099893-5B7D-49E6-8CA5-A53E76F62AC3Q37544479-C686C591-EE2F-40A0-9F2C-3F2F308AC479Q37910251-2BA84363-677E-42E4-8382-CC491AEDBDCFQ37990720-0A0F02A2-BF31-4E42-849C-F1B9389D6802Q38502294-3112D63E-C6F2-4669-AC0C-8AD82AE61CA5Q38502298-320C0BF1-E4AA-4F62-98E6-58D14B766F6BQ38557282-1BB1DA13-B1C8-40F3-98AB-13F78F8E7227Q38805792-B4C8A1FE-54BD-4026-8D10-9520746D93A9Q38979626-285A3CA0-7EF1-4980-BC74-CDFBEF16EF70Q39030684-7D10E962-D375-43CE-B1B0-6F95A8B5EB65Q39456569-9675CB56-1979-4CBA-952A-BA3860EF084EQ41082086-BEA41F30-AE56-44A2-8B46-6BC8854D5B26Q41840976-AB305DC4-FDAC-40B2-8FE6-14346AB81C28Q42189720-0D643FDE-D7BC-40F8-8CC9-0CB26D9087F7Q42263053-992792F5-A9EE-47E9-B4E8-D7DB4A74FBA6Q42281285-5D24A403-2F4E-436A-9161-1555BF1580E0Q47312168-FCA98A44-DECF-47C9-827C-31918F6FEC12Q49193526-FC0816A7-A9AE-4759-94A7-915E08B5F8D6Q57240408-690B90FF-7491-4757-A958-84A2C8EBAAA5
P2860
The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The combination of rifampin pl ...... hollow-fiber infection model.
@en
The combination of rifampin pl ...... hollow-fiber infection model.
@nl
type
label
The combination of rifampin pl ...... hollow-fiber infection model.
@en
The combination of rifampin pl ...... hollow-fiber infection model.
@nl
prefLabel
The combination of rifampin pl ...... hollow-fiber infection model.
@en
The combination of rifampin pl ...... hollow-fiber infection model.
@nl
P2093
P2860
P356
P1433
P1476
The combination of rifampin pl ...... hollow-fiber infection model.
@en
P2093
Adam Eichas
Arnold Louie
David L Brown
G L Drusano
Nicole Sgambati
Robert Kulawy
P2860
P356
10.1128/MBIO.00139-10
P577
2010-08-10T00:00:00Z